Thus, PI3Kδi might be especially useful in patients with high levels of intratumoural Treg cells and an unfavourable ratio of Treg versus CD8+ tumour-infiltrating lymphocytes (TILs) in pre-treatment samples. The gene discussed is CD8A; the disease is neoplasm.